Atara Biotherapeutics to Participate at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today announced that Company management will participate at two upcoming virtual conferences. Stifel 2020 Virtual Healthcare Conference Wednesday, November 18, 2020 at 4:40 p.m. EST F

Click to view original post